FindTrial
Sign In

Catecholamine metabolites and their correlations with biological and clinical features in patients with neuroblastoma

Catecholamine metabolites and their correlations with biological and clinical features in patients with neuroblastoma - Catecholamine metabolites in patients with neuroblastoma

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45532
Enrollment
100
Registered
2017-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Interventions

Catecholamines
Diagnostics
Neuroblastoma
Prognosis

Sponsors

Prinses Máxima Centrum voor Kinderoncologie
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Suspected neuroblastoma patient 2. Urine sample must be available from the moment of diagnosis 3. Histologically proven neuroblastoma

Exclusion criteria

Exclusion criteria: 1. Not neuroblastoma

Design outcomes

Primary

MeasureTime frame
- Urine and plasma catecholamine metabolites levels - Patient characteristics: age and gender - Tumor characteristics: stage, cytogenetics (such as MYCN amplification, LOH 1p, LOH 11q, ALK), MIGB-scan, bone marrow invasion, risk group, MRD -Clinical outcomes (prognosis): primary response to therapy (conform INRG), event-free survival and overall survival—

Countries

Belgium, Germany, Israel, Netherlands, Sweden

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)